Brief: Jasper Therapeutics Announces Briquilimab Development Program In Asthma
13/05/2024 13:15
May 13 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES BRIQUILIMAB DEVELOPMENT
PROGRAM IN
ASTHMA
* JASPER THERAPEUTICS INC: EXPANDING PORTFOLIO OF MAST CELL
PROGRAMS WITH PLANS TO INITIATE A PHASE 1B/2A STUDY IN PATIENTS
WITH ASTHMA IN Q4 2024
Source text for Eikon: ID:nGNX5PhTRY
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma